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Purpose/Objective: The current plan optimization practice 
in radiotherapy involves a time consuming trial-and-error 
loop until the treatment planner finds one single optimal or 
near-optimal plan which is then evaluated by the radiation 
oncologist and the medical physicist (decision makers). In 
contrast, multi-criteria optimization (MCO) aims to avoid the 
iterative optimization loop and to provide alternative choices 
to the decision makers. MCO generates a set of Pareto-
optimal plans which are plans where no criterion can be 
improved without deteriorating another. This set of 
generated decision plans, available for real time navigation 
and decision making, are Pareto optimal in the fluence 
space. The final deliverable plan is created based on the 
navigated plan selected by decision makers, and entails a 
post-optimization step which includes segmentation and a 
final dose calculation. This two-step process could result in 
dosimetric differences between the selected plan and the 
final deliverable one. The purpose of this study was to 
explore the dose difference between navigated and actually 
deliverable plans through the trade-off between two 
evaluation parameters, planning target volume (PTV) under-
dosage and rectum sparing.  
Materials and Methods: Navigated and deliverable VMAT 
plans for five prostate cancer cases were created and 
calculated with RayStation Treatment Planning System. Two-
dimensional Pareto fronts were created corresponding to PTV 
under-dosage vs. rectum sparing. PTV under-dosage was 
evaluated through the volume of PTV receiving less than 95% 
of the prescribed dose and rectum sparing was evaluated 
through the D50% parameter for rectum. In order to minimize 
the effect of the other parameters involved in the treatment 
planning problem and to reduce the multi-dimensionality of 
the problem, we introduced optimization constraints on other 
OARs which ensured minimal dosimetric variations for these 
structures. 
Results: The Pareto front evaluation demonstrated a 
discrepancy for the trade-off parameters between navigated 
and final deliverable plans (see Figure 1). In two of the five 
prostate cases there was an improvement for the deliverable 
plans. For the other cases the discrepancy proved more 
random, resulting in better or worse final plans. Our results 
for prostate cases suggest that the final deliverable plan 
quality may be different from the one that has been used for 
decision making.  
 
Conclusions: The approximation error between the navigated 
and deliverable plans should be estimated and taken into 
consideration in the clinical decision making process when 
MCO is used. 
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Purpose/Objective: Treatment plan evaluation is a clinical 
decision problem with conflicting objectives. In clinical 
practice decision makers perform several clinical judgments 
based on trade-off analysis between tumor coverage and 
healthy tissue sparing in order to conclude if the plan is 
acceptable for treatment. Treatment plan evaluation process 
involves visual search and analysis in a contextually rich 
environment, including delineated structures and isodose 
lines superposed on CT data. Clinical decision making is a 
two-step process including visual analysis and clinical 
reasoning. To our knowledge, there have been no studies 
investigating where decision makers look when they evaluate 
a plan. Additionally, decision makers might not always be 
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consciously aware of how they evaluate a plan or how they 
perform complex clinical judgments. In an approach similar 
to what has been done in radiology, we studied the feasibility 
of using eye-tracking techniques to enhance the 
understanding of how decision makers interact with the given 
visual information during treatment plan evaluation. We 
aimed to verify if eye-fixation positions would be indicative 
of the clinical radiation plan evaluation process.  
Materials and Methods: Single slice dose distributions of 10 
prostate cancer treatment plans were presented to 8 decision 
makers. Their eye-fixation positions were recorded with an 
EyeLink1000 remote eye-tracker. The position was 
determined through pupil and corneal reflection created by 
infrared illumination, with an average accuracy of 0.5°, 
corresponding to 6mm spatial accuracy for our set-up. Total 
evaluation time, dwell time, number and duration of 
fixations on pre-segmented areas of interest involving the 
main structures were measured.  
Results: The median value of time spent by decision makers 
looking at the PTV was 39% (min=3%; max=86%), at the 
rectum 5% (min=0%; max=37%) and at the bladder 17% 
(min=0; max=74%). The remaining time was spent looking at 
femoral heads, isodose lines and information legend 
(structure and isodose colors and values). The relatively long 
time spent on the bladder is probably due to its large volume 
and its central position in the slice, making it the most 
prominent feature. The main structures receiving longer 
fixations (PTV, rectum, bladder) correspond to the main 
trade-offs evaluated in a typical prostate plan. Our results 
show variability among decision makers, indicating that they 
have different behaviors when looking at the plans. 
 
 
 
Typical treatment plan evaluated by a decision maker. Eye-
fixations are the blue circles. The circle diameters represent 
the fixation duration. 
Conclusions: Our study is the first to show the feasibility of 
using the eye-tracking method during radiotherapy treatment 
plan evaluation. The correspondence between where the 
decision makers are looking and how it influences the 
decision process still has to be investigated in details, but our 
results suggest that eye-tracking can be used to explore how 
they visually interact with the given information in order to 
perform clinical judgments.  
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Purpose/Objective: Variability in radiation sensitivity 
between patients has been shown to have a genetic 
component. This genetic component may play an important 
role in explaining the fluctuating rates of radiation-induced 
toxicities (RITs) reported in the literature. However, single 
nucleotide polymorphisms (SNPs) have yielded inconsistent 
results in delineating RITs. Copy number variations (CNVs) 
have been implicated in inflammatory diseases but not yet 
investigated in RITs. Furthermore, clinical and dosimetric 
factors may present confounding effects. Therefore, we are 
evaluating and comparing NTCP data-driven and analytical 
radiogenomic modelling approaches to investigate the 
association of CNVs and SNPs alongside clinical and 
dosimetric variables in late radiation induced rectal bleeding 
(RB) and erectile dysfunction (ED) for prostate cancer 
patients.  
Materials and Methods: A cohort of 100 prostate cancer 
patients who underwent hypofractionated radiotherapy (66 
Gy in 22 fractions) between 2001-2010 was retrospectively 
genotyped for SNPs and sequenced for CNVs. Candidate genes 
were selected based on SNPs previously reported to be 
associated with prostate RITs. Genetic variables consisted of 
SNPs and CNVs of three DNA repair genes (xrcc1, xrcc1, 
ercc2), two growth factors (tgfβ1, vegf) and a radical 
scavenger gene (sod2). Radiogenomic modelling was 
performed using multi-metric data-driven and analytical 
frameworks which were based, respectively, on logistic 
regression data-mining and on the generalized LKB model. 
Performance was evaluated using receiver operating 
characteristic area under the curve (AUC) and statistical 
resampling by cross-validation.  
Results: No clinical variables improved the fit of the models. 
Inclusion of biological variables into the modelling 
frameworks improved the fit of ED and RB analytical and 
data-driven models (Figure 1A,1B). Cross-validated analytical 
model classification performance (AUC) was improved by 
10.2% and 4.8% for RB and ED, respectively, when genetic 
variables were included. Similarly, data-driven models 
increased in AUC by 22.7% and 6.8% for RB and ED, 
respectively (Table 1). 
 
